Supriya Lifescience Limited, a active public limited company, was established on 26 March 2008 in Mumbai, Maharashtra, India. Engaging in api manufacturers within the manufacturing sector, it holds CIN: L51900MH2008PLC180452. Registered under ROC Roc Mumbai. it is listed on BSE: 543434 and NSE: SUPRIYA. It has an authorized capital of ₹35.00 Cr and a paid-up capital of ₹16.10 Cr.
It upholds a compliant status. In 2024, it reported revenue of ₹581.01 Cr and a net worth of ₹815.37 Cr. Employing 450 professional, Its leadership includes Dileep Kumar Jain (Director), Smita Satish Wagh (Whole-Time Director), Neelam Yashpal Arora (Director). Past directors included Dileep Kumar Jain, Asha Waman Wagh, Smita Satish Wagh. It holds ₹262.41 Cr open charges and ₹169.96 Cr settled loans. Its latest AGM occurred on 27 September 2024, with the balance sheet filed on 31 March 2024. It is based at 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East),, Mumbai, Maharashtra, 400063.
L51900MH2008PLC180452
180452
26 March 2008
₹35.00 Cr
₹16.10 Cr
Roc Mumbai
Listed (BSE: 543434, NSE: SUPRIYA)
Active
Explore comprehensive insights into Supriya Lifescience Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Dileep Kumar Jain | Director | 25 Mar 2021 | Current |
| Smita Satish Wagh | Whole-Time Director | 26 Mar 2008 | Current |
| Neelam Yashpal Arora | Director | 25 Mar 2021 | Current |
| Sunil Subhash Bhagwat | Additional Director | 24 Jan 2025 | Current |
| Shivani Satish Wagh | Managing Director | 01 Jul 2022 | Current |
| Saloni Satish Wagh | Managing Director | 01 Jul 2022 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 02 Aug 2021 | Past |
| Pramod Abcsdd | Whole-Time Director | 31 May 2019 | Past |
| Pramod Abcsdd | Whole-Time Director | 31 May 2022 | Past |
| Pramod Abcsdd | Director | 24 Feb 2017 | Past |
| Pramod Abcsdd | Additional Director | 02 Aug 2021 | Past |
| Pramod Abcsdd | Whole-Time Director | 15 Sep 2019 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Supriya Lifescience Limited, for the financial year ended 2024, experienced significant growth in revenue, with a 23.51% increase. The company also saw a substantial improvement in profitability, with a 32.56% increase in profit. The company's net worth Soared by an impressive increase of 16.57%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2024, Supriya Lifescience had a promoter holding of 67.64% and a public holding of 32.35%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹2,624,102,000.00
₹1,699,574,443.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Jun 2025 | Idbi Trusteeship Services Limited | ₹114.00 Cr | Open |
| 03 May 2024 | Axis Bank Limited | ₹44.00 Cr | Open |
| 17 Apr 2024 | Others | ₹30.00 Cr | Open |
| 05 Jul 2012 | The Saraswat Cooperative Bank Ltd | ₹2.00 Cr | Open |
| 27 Jun 2009 | The Saraswat Cooperative Bank Ltd | ₹10.91 Cr | Open |
Explore comprehensive loan charge details -
Supriya Lifescience has a workforce of 450 employees as of Apr 04, 2025. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Supriya Lifescience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Supriya Lifescience's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
A charge with Idbi Trusteeship Services Limited amounted to Rs. 114.00 Cr with Charge ID 101126368 was registered on 26 Jun 2025. was recorded as a recent event.
Progress on Prachi Suhas Sathe was appointed as a Company Secretary was appointed as a Company Secretary on 17 Mar 2025 & has been associated with this company since 9 months 5 days . was documented.
Sunil Subhash Bhagwat was appointed as a Additional Director was appointed as a Additional Director on 24 Jan 2025 & has been associated with this company since 10 months 26 days . was recorded as a recent event.
Progress on Ganapathi Dadasaheb Yadav was appointed as a Additional Director was appointed as a Additional Director on 24 Jan 2025 & has been associated with this company since 10 months 26 days . was documented.
Supriya Lifescience Limited last Annual general meeting of members was held on 27 Sep 2024 as per latest MCA records. was recorded as a recent event.
Progress on A charge with Axis Bank Limited amounted to Rs. 44.00 Cr with Charge ID 100916191 was registered on 03 May 2024. was documented.
Revenues rose 33% YoY to Rs 140 crore in Q3FY24. Earnings before interest, taxes, depreciation and amortisation (EBITDA) for Q3FY24 almost tripled to reach Rs. 41.49 crore, with an EBITDA margin of 29.6% in Q3FY24, as opposed to 13.4%, an improvement of 1620 basis points..
The CIN of Supriya Lifescience Limited is L51900MH2008PLC180452.
Supriya Lifescience Limited is headquartered at 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East),, Mumbai, Maharashtra, 400063.
Supriya Lifescience Limited was incorporated on 26 March 2008.
The current directors of Supriya Lifescience Limited are
The primary industry of Supriya Lifescience Limited is Manufacturing.
Supriya Lifescience Limited is listed. It is listed on BSE: 543434 and NSE: SUPRIYA.
The authorized capital of Supriya Lifescience Limited is ₹35.00 Cr, and the paid-up capital is ₹16.10 Cr.
The compliance status of Supriya Lifescience Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX